Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Beneath the Surface: Moving Beyond Symptomatic Control in Obstructive Hypertrophic Cardiomyopathy

Premiere Date: Wednesday, May 4, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, May 4, 2023
Note: Credit Is No Longer Available

Faculty

Theodore Abraham, MD, FACC (Moderator) Meyer Friedman Distinguished Professor of Medicine Co-Director, University of California at San Francisco HCM Center of Excellence San Francisco, CA

Steve R. Ommen, MD, FACC, FAHA  Professor of Medicine, Mayo Clinic Director, Mayo Hypertrophic Cardiomyopathy Clinic Rochester, MN

Carolyn Yung Ho, MD  Medical Director, Cardiovascular Genetics Center Cardiovascular Division, Brigham and Women's Hospital Harvard Medical School Boston, MA

Statement of Need

Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease, with a highly variable phenotypic expression that ranges from no symptoms to drug-refractory heart failure. HCM is a lifelong condition that can worsen over time and is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Patients may go years without a diagnosis despite being symptomatic, putting them at increased risk for atrial fibrillation, stroke, heart failure, and sudden cardiac death.

To provide the best quality of care and achieve optimal outcomes, it is critical for clinicians to properly screen appropriate patients and determine the etiology of symptoms, which are often non-specific. Genetic testing can help determine if the hypertrophy is associated with mutations in one of several sarcomeric genes which encode components of the contractile apparatus of the heart.

In this CME Outfitters OnDemand symposium from Heart Rhythm 2022, three experts in HCM explore the latest strategies and updates in HCM diagnosis and management, including progress with disease-specific treatments that target cardiac myosin.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Apply current, evidence-based diagnostic and treatment strategies to the care of patients with HCM.
• Assess the chemomechanical cycle of cardiac myosin in HCM and the impact of myosin inhibition on disease factors.
• Evaluate study results of disease-specific treatments targeting cardiac myosin in HCM.

Financial Support

Supported by an educational grant from Bristol Myers Squibb.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in cardiology and electrophysiology

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring activity

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Abraham reports no financial relationships.

Dr. Ommen reports no financial relationships.

Dr. Ho reports the following financial relationships:

Advisory Board: Bristol Myers Squibb

Consultant: Tenaya Therapeutics

Research: Pfizer Inc.

The following peer reviewer and CME Outfitters staff report no financial relationships:

Jeffrey Helfand, DO (peer reviewer)

Warren Beckman (planning committee)

Evan Luberger (planning committee)

Susan H Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).